CrossPoint Therapeutics

Hwaseong, South Korea Founded: 2022 • Age: 4 yrs
Immunotherapies for cancer are developed using antibody platforms.

About CrossPoint Therapeutics

CrossPoint Therapeutics is a Healthcare company based in Hwaseong (South Korea) founded in 2022 by Tae-Erk Kim. Immunotherapies for cancer are developed using antibody platforms. CrossPoint Therapeutics has raised $2.39 million across 1 funding round from investors including Kudos Ventures. Its chief executive, as recorded, is Tae-Erk Kim. CrossPoint Therapeutics offers products and services including Stealth-Body Technology. Its focus areas include Life Sciences, Immunotherapy, Antibody and Disease-Targeting.

Company details

CrossPoint Therapeutics was founded in 2022 and is based in Hwaseong, South Korea. Immunotherapies for cancer treatment are developed through its Stealth-Body technology and Fc inert antibody platform. Antibody therapies include CPP-001 for protein delivery, CPS-001 for small molecule delivery, and CPR-001 for gene delivery. Operations focus on advancing these modalities in the biotechnology sector to address oncology needs.

  • Headquarters Hwaseong, South Korea
  • Founders Tae-Erk Kim
  • Sectors
    Healthcare
  • Email
    β€’β€’β€’β€’β€’β€’β€’β€’
  • Phone
    β€’β€’β€’β€’ β€’β€’β€’β€’
  • Website crosspointrx.com
Key Metrics
  • Total Equity Funding
    $2.39M (USD)

    in 1 rounds

  • Latest Funding Round
    $2.39M (USD), Seed

    Mar 2026

  • Investors

Products & Services of CrossPoint Therapeutics

CrossPoint Therapeutics offers a comprehensive portfolio of products and services, including Stealth-Body Technology.

Stealth-Body Technology
Antibody Platform

Proprietary system for antibodies with reduced Fc-effector functions to limit toxicity.

Funding Insights of CrossPoint Therapeutics

CrossPoint Therapeutics has successfully raised a total of $2.39M through 1 strategic funding round. The most recent funding activity was a Seed round of $2.39 million completed in March 2026. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.

  • Total Funding $2.39M
  • Total Rounds 1
  • Last Round Seed β€” $2.39M
  • First Round $2.39M

    (Mar 2026)

  • Investors Count 1

All 1 funding rounds of CrossPoint Therapeutics with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.

DateAmountTransaction NameValuationLead InvestorsInvestors
Mar 2026$2.39MSeed–Kudos Ventures
–
Valuation history

1 investors in total: 1 institutional.

Investors in CrossPoint Therapeutics

CrossPoint Therapeutics has secured backing from 1 investor, including venture fund investors. Prominent investors backing the company include Kudos Ventures.

All
Venture Fund
InvestorDescriptionFounded YearDomainLocation
kudosventures.co.kr
Premium access

Investor details for CrossPoint Therapeutics

The complete investor list, round-by-round participation and investor portfolios require an active premium plan.

  • Complete investor list
  • Round participation
  • Investor portfolios
  • Co-investor network

Verified entity values are shown only after access is granted.

People of CrossPoint Therapeutics

1 people are tracked at CrossPoint Therapeutics (1 in leadership).

NameRoleGroup
Tae-Erk Kim
Co-Founder & CEOLeadership
Premium access

Complete people profiles for CrossPoint Therapeutics

Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.

  • Full employee list
  • Team structure
  • Board tenure
  • Professional contacts

Verified entity values are shown only after access is granted.

Timeline of CrossPoint Therapeutics

2 dated milestones of CrossPoint Therapeutics across 4 years, from founding to its latest funding, stage changes and deals.

  1. Founded CrossPoint Therapeutics is founded.
  2. Funding First funding round of $2.4M.

Web traffic of CrossPoint Therapeutics

The website of CrossPoint Therapeutics (crosspointrx.com) receives about 2.4K visits a month.

  • Monthly visits
    2.4K

    ▼ 3.2% vs previous month

Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track β€” from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • βœ“
    Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • βœ“
    Full access to every database India & global coverage, advanced filters and rich profile details
  • βœ“
    Always-on access from your team account Single premium plan for everything you see on the portal

Frequently Asked Questions about CrossPoint Therapeutics

CrossPoint Therapeutics was founded in 2022 and raised its 1st funding round 4 years after it was founded.

CrossPoint Therapeutics is headquartered in Hwaseong, South Korea. It is registered at Hwaseong, Gyeonggi Province, South Korea.

Tae-Erk Kim is the CEO of CrossPoint Therapeutics, as recorded in our data. They have also founded this company.

CrossPoint Therapeutics is a funded company, having raised a total of $2.39M across 1 funding round to date. The company's 1st funding round was a Seed of $2.39M, raised on Mar 2026.

CrossPoint Therapeutics was founded in 2022 and is based in Hwaseong, South Korea. Immunotherapies for cancer treatment are developed through its Stealth-Body technology and Fc inert antibody platform. Antibody therapies include CPP-001 for protein delivery, CPS-001 for small molecule delivery, and CPR-001 for gene delivery. Operations focus on advancing these modalities in the biotechnology sector to address oncology needs.

CrossPoint Therapeutics offers Stealth-Body Technology.

CrossPoint Therapeutics has 1 investor. Key investors include Kudos Ventures.

Explore millions of companies β€” effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals β€” all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available